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1. INTRODUCTIONDrug attrition; the gradual reduction of pharmacological compounds while progressing along their development pipeline is the most pressing issue in the pharmaceutical industry over the last few decades. The main reason for drug attrition is the inappropriateness of 
a product with regard to either efficacy or safety. However, 
by the time these concerns are identified; new compounds 
have already entered clinical trials. In 2001, lack of 
efficacy and safety resulted in the withdrawal of ~ 60% of compounds which entered clinical trials1. In 2004, the 
developmental cost of a marketable product was estimated at an escalating US$ 900 million2 and at this time, the US 
FDA had approved 36 new compounds which were later reduced3 to 20 by 2005. In order to reduce drug attrition 
rates as well as incurring developmental costs, evoking an 
in vitro humanised predictive system to evaluate chemical entities along their development pipeline is highly desirable. Animal in vitro and in vivo test systems are currently 
being used to evaluate the efficacy and safety of a potential compound4,5. However, due to species variation and 
pharmaco-toxicological differences, animal toxicological 
test systems are challenging, as results obtained from such models are not ideal representations of what may incur in humans6-8. The large number of animals required for comprehensive toxicological testing also poses a 
significant issue. The requirement for eliminating species 
variation and the constant pressure to minimise the use of test animals further emphasises the need to develop 
novel, robust and economical in vitro humanised models. This is not to say that human test systems are non-existent. 
However, human test systems which include immortalised 
cell lines and primary cell types, do not represent cell types in their natural state with primary cells losing tissue 
specific functions over time.  The derivation of human embryonic stem cells (hESCs) in the late nineties9 and induced pluripotent 
stem cells (hiPSCs) in 2007-0810,11 ushered in a new era 
in basic, translational and clinical research. The ability of human pluripotent stem cells (hPSCs) to self-renew 
and differentiate into virtually any cell type of the three germ layers provides an unparalleled advantage over somatic cell test systems12,13. Their unlimited supply and 
reproducible differentiation14-17 into desired cell types allows for unique opportunities in drug development5,18-21. 
In this mini-review, we direct our focus on the advantages and disadvantages of utilising hPSC-derived cell types as drug discovery platforms with special emphasis on cardio- and hepatotoxicity; forerunners for drug attrition as well as embryotoxicity. 
2.	 Human	 PSC-derived	 CardiomyoCyteSCardiomyocytes are one of the most fundamental cell 
types in cardiac research, however severe limitations in 
obtaining workable human cardiomyocytes significantly hampers their use in pre-clinical drug discovery22. 
Moreover, due to their limited proliferation capacity, 
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term culture, requiring the need for repeated isolation of primary tissue necessary for in vitro functional analysis. 
Currently, canine cardiomyocytes are the most widely used pre-clinical model for assessing cardiotoxicity23. Apart 
from being non-human, ethical concerns surrounding 
the killing of hundreds of dogs annually together with 
substantial costs are major limitations associated with this 
test system. Heterologous over-expression systems which 
include cell lines ectopically expressing specific cardiac ion channels are also utilised as in vitro test systems. However, over-expression of a single ion channel in isolation from a 
complex ion channel network within cardiomyocytes may 
prove to be disadvantageous. The market withdrawal of Vioxx further emphasises as to why in vitro humanised 
models which can predict efficacy and safety with high precision are mandatory5,23.
Blockage of the potassium channel hERG which regulates the IKr current is a key criterion for drug attrition. Proper regulation of IKr is vital for normal cardiac repolarisation and prevention of QT prolongation. The QT interval represents the duration of ventricular depolarisation and subsequent repolarisation and prolongation of this interval to more than 450ms could trigger life-threatening arrhythmias23. Pharmacological 
compounds such as thioridazine, nilotinib and arsenic trioxide are reported to cause QT prolongation. The FDA has thus recognised QT prolongation as an important variable which needs to be addressed during drug development while the International Conference of 
Harmonisation (ICH) Expert Working Group (EWG) for 
drug development has placed risk assessments for delayed ventricular repolarisation as standard procedure of pre-clinical evaluation of new chemical entities24.
Cardiomyocytes differentiated from hPSCs open a new paradigm in regenerative medicine25,26, disease modelling20,27, drug discovery18-20,28 and understanding developmental phenomena17,29. Similar to their adult 
counterparts, hPSC-derived cardiomyocytes express 
cardiac genes, structural proteins and ion channels17,30 as well as exhibit a functional excitation-contraction coupling 
system which could be modulated through β1/β2-adrenergic and muscarinic receptor agonists31. Evaluation of electrophysiological properties could be performed on single cells (patch clamp) or clusters (multi-electrode analysis; MEA) which allow for studying action potential 
(AP) and field potential duration (FPD) respectively 
(apart from other parameters). While the ability to assess 
the effect of a compound on a single ion channel (K+, Na+, Ca2+) or complex channel network (AP, FPD) enhances 
the prediction value of hPSC-cardiomyocytes, the absence of species variation renders these cells an impeccable humanised in vitro test system. A number of studies have demonstrated the potential application of hPSC-cardiomyocytes in evaluating pharmacological safety23,32-
36. For example, while E-4031 (IKr blocker) and Satalol (class III anti-arrhythmic agent; IKs blocker) were reported 
to induce QT prolongation, administration of quinidine 
(class I anti-arrhythmic agent; I
Na
 blocker) and TTX (Na+ 
channel blocker) resulted in a dose-dependent reduction in conduction velocity18,32. 
With the establishment of hiPSC technology, patient-
specific cardiomyocytes could be generated, providing unprecedented insight into the molecular mechanisms surrounding disease pathogenesis20. Testing of compounds 
on patient-specific cardiomyocytes would result in a 
more accurate prediction with regard to efficacy and 
safety. Currently hiPSC models bearing various hERG mutations have been generated for studying congenital Long QT syndrome 2; a familial arrhythmogenic syndrome characterised by delayed repolarisation which could result in life threatening polymorphic ventricular tachycardia20,37,38. 
While LQTS2 cardiomyocytes derived from patient-specific iPSCs recapitulate the disease phenotype (prolonged 
QT interval), treatment with ion channel modulators 
and β-blockers resulted in QT shortening and reduced the incidence of early after depolarisation (EAD) events. Targeting of the proteasomal complex has also proven to be 
successful in reversing the Long QT phenotype, showcasing the tremendous potential of hiPSCs in drug discovery20.
Drawback surrounding hPSC-cardiomyocytes is their failure to completely develop a mature phenotype. Irregular sarcomeric organisation18,31, multi-angular morphologies 
(spindle, round, triangular), absence of a T-tubule system31 
and the expression of foetal proteins (e.g. SMA, Cx45)15,39,40 suggest hPSC-cardiomyocytes are structurally more 
foetal-like in nature. Spontaneous contractions, auto-arrhythmic behaviour and smaller amplitudes of various currents indicate electrical immaturity as well. Based on 
these structural and electrophysiological disparities, when 
compared to adult cardiomyocytes, hPSC-cardiomyocytes 
seem to resemble a 16-week old foetal heart23,41 which may be disadvantageous during pharmacological evaluations. 
For example, dose-response studies have shown that 
hESC-cardiomyocytes respond to isoprenaline at ~10nM42, 
which is similar to a failing heart rather than a health one, 
which responds to ~1-2 nM depending on the age of the individual43.
When using hPSC-cardiomyocytes as a test system, evaluation of a compound focusses primarily on electrophysiological alterations (e.g. QT prolongation). It would be of utmost importance if hPSC-cardiomyocytes could also provide insight into compounds capable of inducing indirect cardiotoxicity. Treatment with anti-
cancer drug trastuzumab (Herceptin); a monoclonal 
antibody administered for breast cancer resulted in a 4% increase in heart failure and decreased heart function 
by 10% especially in patients co-administered with anthracyclines44. Since these side effects were unforeseen 
until phase III studies, adequate end-points should be developed to evaluate all-manner of cardiotoxicity (direct 
and indirect). To circumvent these issues, apart from 
electrophysiological alterations, the secretion of cardiac troponins and natriuretic peptides into culture medium have been used as indicators of potential cardiotoxicity45,46. 
Improved understanding of candidate biomarkers would 
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therefore allow for heightened precision in predicting 
efficacy and safety of a novel chemical entity. 
3.	 	 Human	 PSC-derived	HePatoCyteS
Targeting of liver metabolism, thereby modulating interplay between hepatocytes and other organs is considered a viable solution for metabolic ailments. 
However, more than 40% of new compounds fail their 
clinical phase trials due to unforeseen pharmacokinetic complications47, rendering drug-induced liver toxicity 
a primary reason for attrition. It is estimated that 298 
approved drugs cause hepatotoxicity as a side effect and 
while 6 compounds have been suspended or withdrawn, more than 250 compounds which are associated with acute 
liver failure still remain in the market48. Hepatic death (apoptosis or necrosis) could be induced by a number of 
cellular factors (depletion of glutathione, binding to lipids 
and enzymes, direct targeting of mitochondrial complex and immune reactions)49 with individual risk factors 
(genetic predisposition, differences in liver metabolism and environment) accounting for unforeseen complications50. Isolated human hepatocytes are considered suitable 
in vitro test systems for evaluating drug metabolism and 
toxicity, yet they are associated with severe limitations51. 
Apart from reduced proliferative capacity, primary hepatocytes retain physiological characteristics only for limited periods as most functions are lost during 
culture. Moreover, variation between donors (genetic 
polymorphisms, epigenetic status, health, diet and 
medications) makes unbiased evaluation and interpretation 
challenging. As with cardiomyocytes, species variation strongly hampers the utilisation of animal hepatocytes as test systems and while human hepatocellular carcinoma cell lines may be considered as alternatives to primary 
hepatocytes, these cell types exhibit partial hepatocyte characteristics47,52. Humanised in vitro models capable of mirroring the complexity of hepatocytes with accurate prediction of candidate compounds is therefore highly desirable.
 Human PSCs are an ideal source for obtaining 
functional hepatocytes and as reports suggest, more than 20 research groups are actively involved in attempts 
to optimize differentiation as well as maturation of hepatocytes. Combinations of growth factors and signal activators53-61, co-culture techniques62-64 and various matrices65-67 have been implemented in attempts to induce 
hepatic differentiation. Once generated, hPSC-hepatocytes are reported to exhibit metabolic functionality such as 
glycogen storage, albumin secretion, urea synthesis, uptake 
and release of indocyanine green, AAT secretion and LDL 
uptake53,57,67-69. Regardless of their metabolic functionalities, the most critical aspect for potential application of hPSC-hepatocytes in safety pharmacology and toxicology is their ability to metabolize drugs using phase I and II enzymes which facilitate drug metabolism5. Data based on hPSC-hepatocytes demonstrating phase I and II enzyme activity is still rudimentary with various discrepancies having been reported54,59-61,69-71. The differentiation protocol 
implemented, the hPSC line used, the quality of the standardised adult hepatocytes have been postulated as reasons for these reported discrepancies. Despite many protocols being made available for the 
generation of hPSC-hepatocytes, down-stream cellular characterisation is based solely on gene and protein expression levels62,72. The identity of hPSC-hepatocytes therefore remains an issue as non-hepatic cell types are also 
derived during the differentiation process. Development 
of a cost-effective, universally robust differentiation protocol would greatly assist in circumventing such 
issues. Furthermore, generation of hiPSCs from various ethnic groups and polymorphic variants as well as from 
patients with specific metabolic diseases would allow for 
population-based compound evaluation and influence the 
development of patient-stratified compounds.
4.	 	 Human	 PSCS	 and	 emBryotoxiCity	 	
Adverse effects caused by compounds on the reproductive system or developing embryo (growth 
retardation, malformations or death) is referred to as reproductive toxicology73. While it would be ideal to model the reproductive cycle in vitro, its severe complexity renders it virtually impossible to do so. If the cycle were to 
be broken down into individual segments however, it may be possible to develop a suitable test system. Since this by 
itself is challenging, evaluation of embryotoxicity is still performed on pregnant animals including rats and rabbits. 
The large number of animals required for tests, including 
their offspring makes it a laborious and non-economical test system. As with cardio- and hepatotoxicity animal test 
systems, species variation would thwart accurate prediction of a given compound. An unfortunate example such as the 
thalidomide disaster has urged scientific communities to 
develop alternative methods for testing embryotoxicity, 
such as cell differentiation assays using either primary cells or immortalised cell lines73,74.  
Initially, mouse embryonic stem cells (mESCs) formed the basis of an innovative in vitro test system for screening potential embryotoxic compounds. Mouse ESCs could be 
differentiated into embryoid bodies (EBs) containing the 
three germ layers (ectoderm, mesoderm and endoderm), 
marking the onset of early mammalian embryogenesis, thereby establishing itself as a competent test system75,76. 
When the mESC test (mEST) was compared against two other well-established in vitro models; rat whole-embryo culture 
(WEC) and the micromass (MM) test, in an international validation study funded by ECVAM (European Centre for 
the Validation of Alternative Methods), a 100% prediction rate in the evaluation of strong embryotoxic chemicals was achieved with all 3 in vitro test systems77. Acceptance of the 
mEST along with the WEC and MM test by the regulatory commission was therefore expected78; however, the 
Scientific Advisory Committee (ESAC) of the ECVAM felt that these in vitro test systems were not adequate79. While several strategies have been implemented in attempts to improve mEST80-90, a major concern which remains is the species variation as it would be challenging to evaluate or 
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In an attempt to address species variation, hPSCs have been proposed as suitable models for investigating embryotoxicity91,93,94. For instance, it was shown that 
while retinoic acid (RA) and 13-cis RA (13RA) exerted 
cytotoxic effects on hESCs, only the former compound induced cytotoxicity in mESCs despite both compounds 
being well-known agents of embryotoxicity94. However, 
testing for cytotoxicity is not a sufficient end-point to establish reproductive toxicity and hence incorporation of 
biomarkers to monitor changes in early lineage transcripts and cardiac development has been proposed91,95. In 
comparison to animal models, hPSCs have proven 
their effectiveness as an embryotoxic test system96. For 
example, reversal of arsenic-induced embryotoxicity by monoisoamyl dimercaptosuccinic acid (MiADMSA) was not only observed in pregnant rats but in hESC-EBs as well. 
Furthermore, arsenic at non-cytotoxic concentrations of 0.1 
ng/ml significantly down-regulated genes representing the germ layers which could be abrogated following MiADMSA treatment. These results suggest that while hPSC-EB test 
systems may be ideal for assessing embryotoxicity, its high level of sensitivity would assist in development of 
drugs which could revert or prevent the adverse effects of chemical entities.
 While preliminary studies demonstrate an applicability 
of hPSCs as a viable embryotoxicity test system, certain 
issues are yet to be addressed. Human PSC lines have been reported to demonstrate lineage bias with propensities 
towards specific cell types during differentiation97,98. Since 
lineage biases could lead to inaccurate predictions, it would be important to consider such intrinsic properties prior to selecting hPSC lines for compound evaluation 
studies. Ideally, hESC lines which demonstrate equal bias towards all three germ layers would be the most suitable 
candidates for such studies. When considering economical 
costs, commercial availability of high-throughput screening 
tools like AggreWellsTM (StemCell Technologies, CA) capable of generating large numbers of uniformed sised EBs could accentuate the screening process by allowing for 
evaluation of a large number of chemical entities. Finally, if hESC-based in vitro test systems could provide positive/encouraging evaluations on drugs found to be embryotoxic 
following approval, then perhaps further developments in 
the field may be stimulated.
5.	 	 ConCLuSionS	
While hPSC implementation in therapeutic applications (regenerative medicine and disease modeling) has been 
extensively discussed over the past decade, only recently their potential in drug discovery is being realistically 
unravelled. The human origin, unlimited proliferative 
capacity and differentiation potential of hPSCs offer many 
advantages in biomedical research. Results obtained from proof-of-concept compound evaluation studies renders 
hPSCs a valuable tool for predicting efficacy and safety with high precision. For hPSCs to be successfully implemented 
as a robust drug discovery platform, issues needing to be 
addressed are (a) cost-effective and reproducible ways 
to generate purified cell populations for high-throughput 
screening, (b) development of universal and standardised assays for accurately evaluating toxicity of a chemical 
entity and (c) forging consensus between the scientific 
community, industry and regulators in developing guidelines for such evaluations. 
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